New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2021

Public Deposited

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Choi, A.M.
    • Other Affiliation: Baylor College of Medicine
  • Brenner, M.J.
    • Other Affiliation: University of Michigan Medical School
  • Gorelik, D.
    • Other Affiliation: Houston Methodist Hospital
  • Erbele, I.D.
    • Other Affiliation: Brooke Army Medical Center
  • Crowson, M.G.
    • Other Affiliation: Harvard Medical School
  • Kadkade, P.
    • Other Affiliation: North Shore University Hospital
  • Takashima, M.
    • Other Affiliation: Houston Methodist Hospital
  • Santa Maria, P.L.
    • Other Affiliation: Stanford University
  • Hong, R.S.
    • Other Affiliation: Wayne State University
  • Rose, A.S.
    • Affiliation: School of Medicine, Department of Otolaryngology/Head and Neck Surgery
  • Ostrander, B.T.
    • Other Affiliation: University of California San Diego
  • Rabbani, C.C.
    • Other Affiliation: Case Western Reserve University
  • Morrison, R.J.
    • Other Affiliation: University of Michigan Medical School
  • Weissbrod, P.A.
    • Other Affiliation: University of California San Diego
  • Tate, A.D.
    • Other Affiliation: Brooke Army Medical Center
  • Kain, J.J.
    • Other Affiliation: Houston Methodist Hospital
  • Lina, I.A.
    • Other Affiliation: Johns Hopkins University School of Medicine
  • Shaffer, S.R.
    • Other Affiliation: American Academy of Otolaryngology–Head and Neck Surgery
  • Ahmed, O.G.
    • Other Affiliation: Houston Methodist Hospital
Abstract
  • Objective To evaluate new medical devices and drugs pertinent to otolaryngology-head and neck surgery that were approved by the Food and Drug Administration (FDA) in 2021.Data SourcesPublicly available FDA device and drug approvals from ENT (ear, nose, and throat), anesthesia, neurosurgery, plastic surgery, and general surgery FDA committees. Review Methods FDA device and therapeutic approvals were identified and reviewed by members of the American Academy of Otolaryngology-Head and Neck Surgery's Medical Devices and Drugs Committee. Two independent reviewers assessed the relevance of devices and drugs to otolaryngologists. Medical devices and drugs were then allocated to their respective subspecialty fields for critical review based on available scientific literature. Conclusions The Medical Devices and Drugs Committee reviewed 1153 devices and 52 novel drugs that received FDA approval in 2021 (67 ENT, 106 anesthesia, 618 general surgery and plastic surgery, 362 neurosurgery). Twenty-three devices and 1 therapeutic agent relevant to otolaryngology were included in the state of the art review. Advances spanned all subspecialties, including over-the-counter hearing aid options in otology, expanding treatment options for rhinitis in rhinology, innovative laser-safe endotracheal tubes in laryngology, novel facial rejuvenation and implant technology in facial plastic surgery, and advances in noninvasive and surgical treatment options for obstructive sleep apnea. Implications for Practice FDA approvals for new technology and pharmaceuticals present new opportunities across subspecialties in otolaryngology. Clinicians? nuanced understanding of the safety, advantages, and limitations of these innovations ensures ongoing progress in patient care.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution-NonCommercial 4.0 International
Journal title
  • OTO Open
Journal volume
  • 6
Journal issue
  • 3
Language
  • English
Version
  • Publisher
ISSN
  • 2473-974X
Publisher
  • SAGE Publications Ltd

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 2473974x221126495.pdf 2023-01-12 Public Download